Phase 1 N=32 A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects
Diabetes Mellitus, Type 2
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 0; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Intracerebral Hemorrhage
Primary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014
N/A N=200 Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Management of Anticoagulation
Primary: Mean Percentage of Time in Therapeutic Range — 48; 53 percentage of time — p=0.20
Phase 2 N=75 Injectable Diclofenac for the Prevention of Post-operative Dental Pain
Pain
Primary: Area Under the Curve (AUC) of the Pain Scores. — 6843; 8832; 9998; 7290 mm*minutes
Phase 3 N=2,016 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease
Anemia · Hematologic Diseases · Cardiovascular Diseases
Primary: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death — 351; 347 participants
Phase 3 N=110 Myocardial Ischemia and Transfusion Pilot
Myocardial Infarction · Unstable Angina · Coronary Artery Disease
Primary: Hemoglobin Concentration — 10.30; 9.03; 10.78; 8.98 g/dL — p=<0.001
Phase 2 N=223 Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
Cataract
Primary: Pupil Diameter (mm) During Surgery — 8.0; 8.0; 8.1; 9.0 mm — p=0.0000
Phase 2 N=71 Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Prostate Cancer · Neoplasm Metastasis
Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants
Phase 4 N=471 AUGMENTIN™ in Dental Infections
Focal Infection, Dental
Primary: Percentage of Participants Achieving Clinical Success (Cure or Improvement) Considering Clinical Judgment of the Investigator at the End of Treatment (Day 5 or Day 7)…
Phase 4 N=60 A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
Arsenic Metabolites Measured in Urine
Primary: Change in Urinary % Monomethyl Arsenic — 2.4; 0.24; -0.06; -3.2 percentage of total urinary arsenic
Phase 2 N=172 Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -11.5; -11.3; -12.1; -10.3 units on a scale
Phase 1 N=16 Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
Impaired Liver Function
Primary: Maximum Blood Concentration (Cmax) — 827.5; 587.6; 1589.5; 974.0 ng/L
N/A N=100 Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses
Myopia
Primary: Handling — 8.84; 6.76 units on a scale
N/A N=32 Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Thalassemia
Primary: Report of Pain by Age Group — 23; 61; 18; 51 percentage of participant-cycles — p=<.001
Phase 3 N=20 Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents
Epilepsy
Primary: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) — 7 Participants